Experienced in Childhood Acute Myeloid Leukemia

Dr. Kavitha Beedupalli

Hematology Oncology | Hematology | Oncology
Lsu Health Sciences Center Shreveport Faculty Group Practice
1541 Kings Hwy, 
Shreveport, LA 
Accepting New Patients
Offers Telehealth
Experienced in Childhood Acute Myeloid Leukemia
Lsu Health Sciences Center Shreveport Faculty Group Practice
1541 Kings Hwy, 
Shreveport, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kavitha Beedupalli is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Beedupalli and is rated as an Experienced provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Beedupalli is currently accepting new patients.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in LA
Hospital Affiliations
Ochsner Lsu Health Shreveport
Ochsner Lsu Health Monroe
Ochsner Lsu Health Shreveport-St Mary Medical Cent
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

LSU HEALTH SCIENCES CENTER SHREVEPORT FACULTY GROUP PRACTICE
1541 Kings Hwy, Shreveport, LA 71103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 5 Less Clinical Trials

17 Total Publications

Radiotherapy vs Surgery for Survival and Locoregional Control of Head and Neck Extramedullary Plasmacytoma: A Systematic Review and Meta-Analysis.
Radiotherapy vs Surgery for Survival and Locoregional Control of Head and Neck Extramedullary Plasmacytoma: A Systematic Review and Meta-Analysis.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 29, 2024
Similar Doctors
Advanced in Childhood Acute Myeloid Leukemia
Dr. Richard P. Mansour
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Richard P. Mansour
Hematology Oncology | Hematology | Oncology

Lsu Health Sciences Center Shreveport Faculty Group Practice

1541 Kings Hwy, 
Shreveport, LA 
 (0.1 mi)
318-675-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Mansour is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Mansour and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mansour is currently accepting new patients.

Advanced in Childhood Acute Myeloid Leukemia
Dr. Maxwell C. Mcdonald
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Maxwell C. Mcdonald
Hematology Oncology | Hematology | Oncology

Wk Hematology Oncology Associates

2600 Kings Hwy, Suite 340, 
Shreveport, LA 
 (1.0 mi)
318-212-8620
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Maxwell Mcdonald is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Mcdonald and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma. Dr. Mcdonald is currently accepting new patients.

Advanced in Childhood Acute Myeloid Leukemia
Dr. Samip R. Master
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Samip R. Master
Hematology Oncology | Hematology | Oncology

Wk Hematology Oncology Associates

2600 Kings Hwy, Suite 340, 
Shreveport, LA 
 (1.0 mi)
318-212-8620
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samip Master is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Master and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Sickle Cell Disease, Acute Myeloid Leukemia (AML), Paget Disease of the Breast, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Master is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Beedupalli's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile